Peanut oral immunotherapy may improve health‐related quality of life among severe peanut allergic adolescents.

Our aim was therefore to investigate if treatment with peanut OIT (pOIT) in combination with omalizumab improves self-reported HRQoL among adolescents with severe peanut allergy. To measure HRQoL, the food allergy questionnaire Food Allergy Quality of Life Questionnaire-Teenager Form (FAQLQ-TF) was used. Peanut allergy is one of the major food allergies, and has an impact on the health-related quality of life (HRQoL).[1] As for today there is no curative treatment, however guidelines recommend oral immunotherapy (OIT) as a therapeutic option to increase the threshold for reactions in children with persistent peanut allergy.[[2]] In line with the guidelines, measurements of treatment effect should include patient-reported outcomes such as HRQoL. [Extracted from the article]